Journal
BIOCONJUGATE CHEMISTRY
Volume 20, Issue 6, Pages 1251-1255Publisher
AMER CHEMICAL SOC
DOI: 10.1021/bc9001163
Keywords
-
Categories
Funding
- NCI NIH HHS [U54 CA119349, U54 CA119349-040003, UU54-CA126515, U24-CA092782, U54-CA119349, U54 CA126515-040002, U24 CA092782, U24 CA092782-08, U54 CA126515] Funding Source: Medline
- NHLBI NIH HHS [U01 HL080731, U01-HL080731, U01 HL080731-04] Funding Source: Medline
Ask authors/readers for more resources
Thrombosis underlies numerous life-threatening cardiovascular syndromes. Development of thrombosis-specific molecular imaging agents to detect and monitor thrombogenesis and fibrinolysis in vivo could improve the diagnosis, risk stratification, and treatment of thrombosis syndromes. To this end, we have synthesized efficient multimodal nanoagents targeted to two different constituents of thrombi, namely, fibrin and activated factor XIII. These agents are targeted via the conjugation of peptide-targeting ligands to the surface of fluorescently labeled magnetic nanoparticles. As demonstrated by in vitro and in vivo studies, both nanoagents possess high affinities for thrombi, and enable mutimodal fluorescence and magnetic resonance imaging.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available